despite treatment with bDMARDs. This recommendation reflects growing understanding about the roles of specific cytokines in systemic JIA and the ability to induce remission with targeted therapy against IL-6 and IL-1 The use of IAGCs was extensively discussed. Recommendations from 2011 and 2019 to preferentially use triamcinolone hexacetonide for oligoarthritis There is much that remains to be learned. Studies must be performed to obtain high-quality data to fill in the evidentiary gaps